Objective: To investigate the clinical characteristics of patients with rheumatoid arthritis (RA)-associatedlung diseases.Methods: A total of 261 patients with RA who were treated with biological agents between August2016 and June 2018 were retrospectively analyzed. Clinical characteristics, serological data, and imageswere collected. RA-associated lung diseases, including pulmonary parenchymal disease [interstitiallung disease (ILD)] and airway disease (bronchiectasis or obliterative bronchiolitis), were identified byone rheumatologist and one pulmonologist. ILD was diagnosed based on the 2013 idiopathic interstitialpneumonias (IIP) classification criteria. The characteristics were compared between two groups of patientswith RA: with and without RA-associated lung diseases.Results: RA-associated lung diseases were detected in 37 (14.1%) of 261 patients with RA. Patientswith RA-associated lung disease were observed to be older and have higher smoking rates and a higherproportion of anti-cyclic citrullinated peptides (anti-CCP) antibody positivity in comparison to thosewithout lung disease (p < 0.05). The highest levels of erythrocyte sedimentation rate (ESR), rheumatoidfactor-IgM, and anti-CCP antibodies during the disease course were also significantly higher in patientswith RA-associated lung disease than in those without lung diseases (p < 0.05).Conclusions: Older patients with RA who smoke and have high levels of RF or anti-CCP antibodiesshould be screened for lung involvement.